4724.TWO Meribank Biotech Co., Ltd

Healthcare Biotechnology Taiwan OTC Exchange
8.88 TWD
Close of Nov 6, 2026
7.94 17.40
Market cap
TWD 852M
P/E
-
P/B
0.74x
ROE
-6.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 4724.TWO undervalued?

Graham number

The Graham number of Meribank Biotech Co., Ltd cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Meribank Biotech Co., Ltd fundamental analysis

No fundamental analysis for Meribank Biotech Co., Ltd yet.

Meribank Biotech Co., Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Meribank Biotech Co., Ltd

Meribank Biotech Co., Ltd researches, develops, manufactures, and stores mesenchymal stem cells in Taiwan. The company engages in the detection, extraction, cryopreservation, archiving, and storage of umbilical cord blood, placental and umbilical cord mesenchymal stem cells, adult peripheral blood stem cells, and immune cells. It also provides cell cryopreservation services. The company was founded in 2001 and is based in Taipei, Taiwan.

Full company profile